EVOQUE TTVR Delivers Promising Real-World Results: Over 97 Percent Achieve TR Elimination

USA: The first large-scale real-world analysis of the EVOQUE transcatheter tricuspid valve replacement (TTVR) system has demonstrated promising safety and efficacy outcomes among patients with severe tricuspid regurgitation (TR). Findings from 1,034 patients enrolled in the STS/ACC TVT Registry were presented as a Late-Breaking Clinical Trial at TCT 2025 , providing encouraging evidence of the device’s effectiveness outside controlled clinical settings. The results reaffirm the clinical benefits of the EVOQUE system (Edwards Lifesciences)—the first FDA-approved transcatheter valve therapy for severe TR. Notably, the improvements in symptoms, survival, and quality of life previously reported in the pivotal TRISCEND II trial were replicated in this broader, real-world cohort treate